Cleared Traditional

K160252 - OmniPod Insulin Management System

K160252 is an FDA 510(k) clearance for OmniPod Insulin Management System, manufactured by Insulet Corporation. The device is a Class 2 General Hospital device with product code LZG cleared through the Traditional 510(k) pathway after a 86-day FDA review.

K160252 · Insulet Corporation · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2016
Decision
86d
Days
Class 2
Risk

K160252 is an FDA 510(k) clearance for the OmniPod Insulin Management System. Classified as Pump, Infusion, Insulin (product code LZG), Class II - Special Controls.

Submitted by Insulet Corporation (Billerica, US). The FDA issued a Cleared decision on April 27, 2016 after a review of 86 days - a notably fast clearance cycle.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5725 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Insulet Corporation devices

FDA 510(k) Submission Details - K160252

510(k) Number K160252 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 01, 2016
Decision Date April 27, 2016
Days to Decision 86 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
43d faster than avg
Panel avg: 129d · This submission: 86d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LZG Device Classification - Class 2, Special Controls

Product Code LZG Pump, Infusion, Insulin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.5725
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.

Regulatory Peers - LZG Pump, Infusion, Insulin

All 50
Devices cleared under the same product code (LZG) and FDA review panel - the closest regulatory comparables to K160252.
t:slim Insulin Delivery System, t:flex Insulin Delivery System, Tandem Device Updater
K162080 · Tandem Diabetes Care, Inc. · Oct 2016
t:slim Insulin Delivery System
K160056 · Tandem Diabetes Care, Inc. · Jul 2016
t:slim Insulin Delivery System, t:flex Insulin Delivery System, Tandem Device Updater
K160482 · Tandem Diabetes Care, Inc. · Jul 2016
t:flex Insulin Delivery System
K143189 · Tandem Diabetes Care, Inc. · Jan 2015
OMNIPOD INSULIN MANAGEMENT SYSTEM
K140439 · Insulet Corporation · Nov 2014
T:SLIM INSULIN DELIVERY SYSTEM
K141758 · Tandem Diabetes Care, Inc. · Oct 2014